NCT01056783

Proof of Concept Study of OC000459 in Eosinophilic Esophagitis

A Randomized, Placebo-controlled, Double-blind, Single-centre Proof-of-concept Study of OC000459 in Adult Patients With Active Eosinophilic Esophagitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Oxagen Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This will be a randomised, double blind, placebo controlled, parallel group evaluation of the effect of OC000459 given orally for eight weeks on active eosinophilic esophagitis.

Conditions

• Eosinophilic Esophagitis

Interventions

Type	Name	Description
DRUG	OC000459	OC000459 100mg, twice daily, tablet
DRUG	Placebo	Placebo tablets to match OC000459 tablets, twice daily

Timeline

• Start date: 2010-08-01
• Primary completion: 2011-06-01
• Completion: 2011-06-01
• First posted: 2010-01-26
• Last updated: 2012-01-05

Locations

1 site across 1 country: Switzerland